Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 3, 2008, Pages 150-157

  Yano, Ikuko ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Calcineurin; Cyclosporine; Pharmacodynamics; Tacrolimus; Therapeutic drug monitoring; Transplantation

Indexed keywords

BINDING PROTEIN; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOPHILIN; PHOSPHATASE; TACROLIMUS; CALCINEURIN PHOSPHATASE; IMMUNOSUPPRESSIVE AGENT;

ACUTE DISEASE; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; REVIEW; T LYMPHOCYTE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METHODOLOGY; MONONUCLEAR CELL; TRANSPLANTATION;

CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; PHOSPHORIC MONOESTER HYDROLASES; TACROLIMUS; TRANSPLANTATION;

EID: 48849092136     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.150     Document Type: Review

References (56)

1. O'Grady, J. G., Burroughs, A., Hardy, P., Elbourne, D. and Truesdale, A.: Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet, 360: 1119-1125 (2002).
2. Kelly, D., Jara, P., Rodeck, B., Lykavieris, P., Burdelski, M., Becker, M., Gridelli, B., Boillot, O., Manzanares, J. and Reding, R.: Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet, 364: 1054-1061 (2004).
3. Liu, J., Farmer, J. D. Jr., Lane, W. S., Friedman, J., Weissman, I. and Schreiber, S. L.: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 66: 807-815 (1991).
4. Fruman, D. A., Klee, C. B., Bierer, B. E. and Burakoff, S. J.: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc. Natl. Acad. Sci. U.S.A., 89: 3686-3690 (1992).
5. Rusnak, F. and Mertz, P.: Calcineurin: form and function. Physiol. Rev., 80: 1483-521 (2000).
6. Staatz, C. E. and Tett, S. E.: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet., 43: 623-653 (2004).
7. Ptachcinski, R. J., Venkataramanan, R. and Burckart, G. J.: Clinical pharmacokinetics of cyclosporin. Clin. Pharmacokinet., 11: 107-132 (1986).
8. Yasuhara, M., Hashida, T., Toraguchi, M., Hashimoto, Y., Kimura, M., Inui, K., Hori, R., Inomata, Y., Tanaka, K. and Yamaoka, Y.: Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant. Proc., 27: 1108-1110 (1995).
9. Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V.,.McMichael, J., Lever, J., Burckart, G. and Starzl, T.: Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet., 29: 404-430 (1995).
10. Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H. L., Turgeon, D. K., Schmiedlin-Ren, P, Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z. and Watkins, P. B.: Role of intestinal Pglycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther., 62: 248-260 (1997).
11. Zhang, Y. and Benet, L. Z.: The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 40: 159-168 (2001).
12. Hashida, T., Masuda, S., Uemoto, S., Saito, H., Tanaka, K. and Inui, K.: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther., 69: 308-316 (2001).
13. Masuda, S., Goto, M., Kiuchi, T., Uemoto, S., Kodawara, T., Saito, H., Tanaka, K. and Inui, K.: Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living-donor liver transplantation. Liver Transpl., 9: 1108-1113 (2003).
14. Masuda, S., Uemoto, S., Goto, M., Fujimoto, Y., Tanaka, K. and Inui, K.: Tacrolimus therapy according to mucosal MDR1 levels in recipients of small bowel transplantation. Clin. Pharmacol. Ther., 75: 352-361 (2004).
15. Masuda, S. and Inui, K.: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol. Ther., 112: 184-198 (2006).
16. Fukudo, M., Yano, I., Masuda, S., Goto, M., Uesugi, M., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Egawa, H., Uemoto, S. and Inui, K.: Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther., 80: 331-345 (2006).
17. Fukudo, M., Yano, I., Yoshimura, A., Masuda, S., Uesugi, M., Hosohata, K., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Uemoto, S. and Inui K.: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics, 18: 413-423 (2008).
18. Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda, M., Tanaka, K. and Inui, K.: CYP3A5* 1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics, 14: 471-478 (2004).
19. Uesugi, M., Masuda, S., Katsura, T., Oike, F., Takada, Y. and Inui, K.: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics, 16: 119-127 (2006).
20. Masuda, S., Goto, M., Fukatsu, S., Uesugi, M., Ogura, Y., Oike, F., Kiuchi, T., Takada, Y., Tanaka, K. and Inui, K.: Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pharmacol. Ther., 79: 90-102 (2006).
21. Staatz, C. E., Taylor, P. J., Lynch, S. V. and Tett, S. E.: A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. Liver Transpl., 10: 506-512 (2004).
22. Scholten, E. M., Cremers, S. C., Schoemaker, R. C., Rowshani, A. T., van Kan, E. J., den Hartigh, J., Paul, L. C. and de Fijter, J. W.: AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int., 67: 2440-244 (2005).
23. Frey, F. J., Horber, F. F. and Frey, B. M.: Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clin. Pharmacol. Ther., 43: 55-62 (1988).
24. Grant, D., Kneteman, N., Tchervenkov, J., Roy, A., Murphy, G., Tan, A., Hendricks, L., Guilbault, N. and Levy, G.: Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation, 67: 1133-1137 (1999).
25. Barone, G., Chang, C. T., Choc, M. G. Jr., Klein, J. B.,Marsh, C. L., Meligeni, J. A., Min, D. I., Pescovitz, M. D., Pollak, R., Pruett, T. L., Stinson, J. B., Thompson, J. S., Vasquez, E., Waid, T., Wombolt, D. G. and Wong, R. L.: The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation, 61: 875-880 (1996).
26. Belitsky, P., Dunn, S., Johnston, A. and Levy, G.: Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin. Pharmacokinet., 39: 117-125 (2000).
27. Maharati, K., Belitsky, P., Sketris, I., West, K. and Panek, R.: Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation, 15: 55-62 (1999).
28. Cantarovich, M., Barkun, J. S., Tchervenkov, J. I., Besner, J. G., Aspeslet, L. and Metrakos, P.: Comparison of neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation, 66: 1621-1627 (1998).
29. 2). Transplantation, 73: 953-959 (2002).
30. Villamil, F. and Pollard, S.: C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl., 10: 577-583 (2004).
31. 2 monitoring of cyclosporine microemulsion. Transplantation, 27: 903-908 (2003).
32. 2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation, 77: 1632-1638 (2004).
33. Nashan, B., Bock, A., Bosmans, J. L., Budde, K., Fijter, H., Jaques, B., Johnston, A., Lück, R., Midtvedt, K., Pallardó, L. M., Ready, A., Salamé, E., Salizzoni, M., Suarez, F. and Thervet, E.: Use of Neoral C monitoring: a European consensus. Transpl. Int., 18: 768-778 (2005).
34. Jorgensen, K. A., Koefoed-Nielsen, P. B. and Karamperis, N.: Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand. J. Immunol., 57: 93-98 (2003).
35. Fukudo, M., Yano, I., Masuda, S., Okuda, M. and Inui, K.: Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. J. Pharmacol. Exp. Ther., 312: 816-825 (2005).
36. Pai, S. Y., Fruman, D. A., Leong, T., Neuberg, D., Rosano, T. G., McGarigle, C., Antin, J. H. and Bierer, B. E.: Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood, 84: 3974-3979 (1994).
37. Batiuk, T. D., Pazderka, F., Enns, J., DeCastro, L. and Halloran, P. F.: Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J. Clin. Invest., 96: 1254-60 (1995).
38. Batiuk, T. D., Pazderka, F. and Halloran, P. F.: Calcineurin activity is only partially inhibited in leukocytes of cyclosporinetreated patients. Transplantation, 59: 1400-1404 (1995).
39. Piccinini, G., Gaspari, F., Signorini, O., Remuzzi, G. and Perico, N.: Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. Transplantation, 61: 1526-1531 (1996).
40. Halloran, P. F., Helms, L. M., Kung, L. and Noujaim, J.: The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation, 68: 1356-1361 (1999).
41. Caruso, R., Perico, N., Cattaneo, D., Piccinini, G., Bonazzola, S., Remuzzi, G. and Gaspari, F.: Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin. Chem., 47: 1679-1687 (2001).
42. Milláan, O., Brunet, M., Campistol, J. M., Faura, A., Rojo, I., Vidal, E., Jiménez, O., Vives, J., Oppenheimer, F. and Martorell, J.: Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin. Chem., 49: 1891-1899 (2003).
43. 2. Int. Immunopharmacol., 3: 987-999 (2003).
44. Sanquer, S., Schwarzinger, M., Maury, S., Yakouben, K., Rafi, H., Pautas, C., Kuentz,M., Barouki, R. and Cordonnier, C.: Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation. Transplantation, 77: 854-858 (2004).
45. Fukudo, M., Yano, I., Masuda, S., Fukatsu, S., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Tanaka, K. and Inui, K.: Pharmacodynamic analysis of tacrolimus and cyclosporine in livingdonor liver transplant patients. Clin. Pharmacol. Ther., 78: 168-81 (2005).
46. Koefoed-Nielsen, P. B., Karamperis, N., Højskov, C., Poulsen, J. H. and Jørgensen, K. A.: The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients. Transpl. Int., 19: 821-827 (2006).
47. Fukudo, M., Yano, I., Masuda, S., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Tanaka, K. and Inui, K.: Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing. Liver Transpl., 12: 292-300 (2006).
48. Koefoed-Nielsen, P. B., Gesualdo, M. B., Poulsen, J. H. and Jørgensen, K. A.: Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am. J. Transplant., 2: 173-178 (2002).
49. Blanchet, B., Hulin, A., Duvoux, C. and Astier, A.: Determination of serine/threonine protein phosphatase type 2B (PP2B) in lymphocytes by HPLC. Anal. Biochem., 312: 1-6 (2003).
50. Batiuk, T. D., Kung, L. and Halloran, P. F.: Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J. Clin. Invest., 100: 1894-901 (1997).
51. Stein, C. M., Murray, J. J. and Wood, A. J.: Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin. Chem., 45: 1477-1484 (1999).
52. Kung, L. and Halloran, P. F.: Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation, 70: 327-35 (2000).
53. Xu, X., Su, B., Barndt, R. J., Chen, H., Xin, H., Yan, G., Chen, L., Cheng, D., Heitman, J., Zhuang, Y., Fleischer, S. and Shou, W.: FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Transplantation, 73: 1835-1838 (2002).
54. Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H. and Back, D. J.: A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J. Immunol. Methods, 274: 129-37 (2003).
55. Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Tanaka, K., Uemoto, S. and Inui, K.: Relation between mRNA Expression Level of MDR1/ ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-donor Liver Transplantation. J. Pharmacol. Exp. Ther., 325: 610-616 (2008).
56. + T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation, 77: 1815-1820 (2004).